We are live on ! Find out more
EW icon

Edwards Lifesciences

1,260 hedge funds and large institutions have $39.3B invested in Edwards Lifesciences in 2025 Q2 according to their latest regulatory filings, with 163 funds opening new positions, 422 increasing their positions, 459 reducing their positions, and 92 closing their positions.

New
Increased
Maintained
Reduced
Closed

77% more first-time investments, than exits

New positions opened: 163 | Existing positions closed: 92

70% more call options, than puts

Call options by funds: $254M | Put options by funds: $149M

7% more capital invested

Capital invested by funds: $36.6B → $39.3B (+$2.64B)

4% more funds holding

Funds holding: 1,2061,260 (+54)

0% more funds holding in top 10

Funds holding in top 10: 1010 (0)

0.6% less ownership

Funds ownership: 86.28%85.68% (-0.6%)

8% less repeat investments, than reductions

Existing positions increased: 422 | Existing positions reduced: 459

Holders
1,260
Holders Change
+54
Holders Change %
+4.48%
% of All Funds
16.55%
Holding in Top 10
10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.13%
New
163
Increased
422
Reduced
459
Closed
92
Calls
$254M
Puts
$149M
Net Calls
+$105M
Net Calls Change
+$25.1M

EW Hedge Fund Activity: Q2 2025 in Review

1,260 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q2 2025, worth a combined $39.3B — up 7.2% from $36.6B a quarter earlier.

Buyers outnumbered sellers: 163 funds opened new EW positions and 92 closed out — a net gain of 71 holders — while 422 added to existing stakes and 459 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $359M. The largest seller was Fisher Asset Management, cutting an estimated $730M.

  • 1,260 institutional investors held Edwards Lifesciences (EW) as of Q2 2025, up from 1,206 in Q1 2025.
  • Funds reported $39.3B of Edwards Lifesciences stock for Q2 2025, up 7.2% quarter-over-quarter.
  • 163 funds opened new Edwards Lifesciences positions in Q2 2025 and 92 closed out, a net change of +71 holders.
  • The largest Edwards Lifesciences buyer in Q2 2025 was JP Morgan Chase, an estimated $359M added.
  • The largest Edwards Lifesciences seller in Q2 2025 was Fisher Asset Management, an estimated $730M sold.

Based on aggregated 13F filings for Q2 2025.